This has reference to the press release issued by the Company today titled Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz .In this regard, please find enclosed herewith disclosure under Regulation 30 of SEBI Listing Regulations.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science, through its Swiss step-down subsidiary SPIAG, is acquiring and in-licensing a portfolio of branded generic products from Sandoz AG for the Sub-Saharan Africa (SSA) region. The deal covers four key markets — Western Sahara, Ghana, Nigeria, and Kenya — and includes products in anti-infective, cardiovascular, and dermatology segments, with several brands each generating annual sales above USD 1 million. Upfront consideration is USD 12 million, payable at closing, plus ongoing royalty payments to Sandoz based on a percentage of net sales. Strides expects this to make it one of the top 5 pharma companies in the SSA region by sales. The transaction is expected to close by end of Q2 FY27 (September 2026), subject to customary antitrust filings.
The acquisition strengthens Strides' Africa business and expands its branded generics portfolio in a high-growth region, though the USD 12 million upfront is modest in size. The deal is not classified as a related party transaction, and there is no material financial impact on the listed entity in India, with the corporate guarantee by its Singapore subsidiary treated as a contingent liability. Shareholders should view this as a strategic, tuck-in expansion of the company's Africa franchise.